Gastric Cancer Information Center
Knowledge is power. Are you facing a new diagnosis, recurrence, living with metastatic disease, or supporting a loved one through their cancer journey? The Cancer Connect Gastric Cancer Information Center has current, evidence-based information for you. Get the facts about gastric cancer prevention, early detection, treatment, and survivorship, and stay up to date with ongoing gastric cancer research that could impact your treatment decisions through our daily cancer news.
You are not alone—The CancerConnect Gastric Cancer Community is the leading Social Media Application for Gastric Cancer patients and caregivers seeking information, inspiration, and support in the wake of a cancer diagnosis. With over 50,000 members the network offers patients and caregivers a thriving community to support the many ongoing needs from diagnosis to survivorship. Login or register here.
Will H. pylori be targeted for full eradication? New Drug Combination Boosts Survival in Advanced Stomach and Esophageal Cancers
Promising new drug combination when bevacizumab added to standard drug combination Reolysin® Receives FDA Designation for Gastric Cancer
New virus therapy granted Orphan Drug Designation
Cancer and its treatment can come with a variety of complications, some more serious... Advanced Directives
Living Wills Every competent adult has, in most cases, the freedom to accept or refuse... Caregivers
What is Caregiving and Who are Caregivers? Caregivers are individuals who provide...
Gastric Cancer Management
Moving On Aerobics helps women regain joy of movement and physical fitness after... Where Kids Can Be Kids… And Cancer Takes a Back Seat
Cancer camps for kids provide fun and camaraderie for children facing down a cancer... Pay it Forward
Survivors become peer mentors to newly diagnosed women and offer experience, insight,...
Gastric Cancer Clinical Trials
USOR06054 – A Randomized Phase II Study of Docetaxel in Combination with Oxaliplatin with or without 5-FU or Capecitabine in Metastatic or Locally Recurrent Gastric Cancer previously untreated with Chemotherapy for Advanced Disease (GATE Study)
Z9001 – A Phase III Randomized Double-blind Study of Adjuvant STI571 (Gleevec) Versus Placebo in Patients Following The Resection of Primary GastroIntestinal Stromal Tumor (GIST)
REFMAL39 – A Phase I, Open-Label, Dose-Escalation Study of SB-715992 Administered Weekly for Three Consecutive Weeks of 28-Day Cycle in Patients with Solid Tumors